Boston Scientific Corporation (NYSE: BSX) reported strong financial results for the first quarter of 2024, driven by growth in its diversified businesses. Net sales increased by 13.8% on a reported basis, 15.0% on an operational basis, and 13.1% on an organic basis compared to the prior year. The company also raised its full-year guidance, reflecting continued momentum.